The review begins by delving into lumateperone's mechanism of action, which involves the partial agonism of the dopamine D2 receptor as well as its unique effects on the dopamine transporter, N-methyl-D-aspartate (NMDA) receptor, and serotonin transporter. Additionally, the study examines lu...
Exact mechanism of action in schizophrenia and bipolar depression unknown; efficacy may be mediated through antagonist activity at central serotonin type 2A (5-HT2A) receptors and postsynaptic antagonist activity at dopamine type 2 (D2) receptors. Exhibits high binding affinity for 5-HT2A receptors ...
“We are pleased with the FDA’s designation of lumateperone for Fast Track development,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. “Given the important safety and tolerability limitations of existing antipsychotics, we believe th...
CAPLYTA 42mg/day is an oral, once daily atypical antipsychotic approved for the treatment of schizophrenia of adults. While the mechanism of action of CAPLYTA in the treatment of schizophrenia is unknown, the efficacy of CAPLYTA could be mediated through...
Lumateperone (ITI-007) is a tosylate salt with binding affinities to receptors implicated in the therapeutic actions of antipsychotic medications, including the serotonin 5HT2A receptors, dopamine D2 and D1 receptors and the serotonin transporter. It has a unique mechanism of action because it ...
Interestingly, it has a similar structure and mechanism of action to paliperidone, the only Food and Drug Administration-approved medication for schizoaffective disorder. Through this case report, as an example of lumateperone's effectiveness and tolerability, as well as ...
The computational methods (molecular docking and simulation) are the best approaches to study this type of binding mechanism before experimental studies, which are costly and take more time. In addition, the enhancement in the reliability, speed, and accuracy of computational docking approaches in ...